These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 30828771

  • 1. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE.
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
    Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE.
    Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
    [Abstract] [Full Text] [Related]

  • 4. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E, Horinaka S, Ishimitsu T, Kato T.
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail.
    Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G.
    Clin Pharmacokinet; 2022 Jan; 61(1):97-109. PubMed ID: 34273071
    [Abstract] [Full Text] [Related]

  • 11. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K.
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
    Lindahl S, Dyrkorn R, Spigset O, Hegstad S.
    Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
    Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C, Working Group Members.
    Thromb Haemost; 2020 Jan; 120(1):132-140. PubMed ID: 31705521
    [Abstract] [Full Text] [Related]

  • 16. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
    Lin SY, Kuo CH, Yeh SJ, Tsai LK, Liu YB, Huang CF, Tang SC, Jeng JS.
    Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H, Rasmusson A, Söderblom L, Malmström RE, Antovic J.
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [Abstract] [Full Text] [Related]

  • 19. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
    Zhao Y, Couchman L, Kipper K, Arya R, Patel JP.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May 01; 1144():122095. PubMed ID: 32251991
    [Abstract] [Full Text] [Related]

  • 20. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
    Cini M, Legnani C, Padrini R, Cosmi B, Dellanoce C, De Rosa G, Marcucci R, Pengo V, Poli D, Testa S, Palareti G.
    Int J Lab Hematol; 2020 Apr 01; 42(2):214-222. PubMed ID: 32039550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.